ClinicalTrials.gg
Status unknownNCT04840745Updated Apr 19, 2021

The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1

A Phase 1 interventional study of CKD-841 A-1 3.75mg and CKD-841 A-1 1.88mg in Early Puberty, sponsored by Chong Kun Dang Pharmaceutical. Status unknown at 1 site in Korea, Republic of. Open to female participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-19.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.

Planned enrollment
13th of 14
32 · median 68
Started
2021
the only one that year
Phase 1
2 of 14
none open now
Registered
12th of 14
by date
Lead sponsor
1 of 14
Chong Kun Dang Pharmaceutical

Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 13th largest by planned enrollment, is the only one that started in 2021, is one of 2 in phase 1, and was the 12th registered.

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

Browse Puberty, Precocious studies →

Open to participants now

2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 40 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing leuprolide in Puberty, Precocious, or all of them as a file.
02

Study summary

A randomized, single-blinded, parallel design phase I clinical trial to investigate the safety and pharmacokinetics/pharmacodynamics of CKD-841 A-1, CKD-841 D or Leuplin Inj. after subcutaneous injection in postmenopausal female

Read the detailed description

To investigate the safety and pharmacokinetics/pharmacodynamics of CKD-841 A-1, CKD-841 D or Leuplin Inj. 3.75 mg after subcutaneous injection in postmenopausal female

03

Conditions studied

  • Early Puberty

Browse trials for

Keywords

  • CKD-841
  • Postmenopausal
  • Leuplin
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy menopausal female
  • β-hCG is negative at screening and before administration of drug
  • Infertility by sterilization operation before 5 months from screening excluding ovarian cancer, uterine cancer etc.
  • Bwt ≥ 50Kg and (BMI) ≥ 18.5 and \< 28.0

Exclusion criteria

Exclusion Criteria:

  • History or current condition of disease related to Hepato-biliary system, renal system, nervous system, mental illness, immune system, respiratory system, endocrine system, hemato-oncology, circulatory system, musculoskeletal system or except for that, significant clinical disease
  • Uncontrolled diabetes mellitus in the last three months
  • Pregnancy or breast feeding
  • History of taking medicine such as Leuprorelin acetate or similar affiliation drug within 12 weeks before administration of drug
  • Has to the active ingredient or or same affiliation drug of the investigational drug, hypersensitivity of a medicine contained gelatin especially
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    CKD-841 A-1(=leuprorelin acetate 3.75mg)

    Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.

    Drug: CKD-841 A-1 3.75mg

  • Experimental
    CKD-841 A-1(=leuprorelin acetate 1.88mg)

    Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.

    Drug: CKD-841 A-1 1.88mg

  • Experimental
    CKD-841 D(=leuprorelin acetate 2.92mg)

    Investigational drug(=CKD-841 D) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.

    Drug: CKD-841 D 2.92mg

  • Active comparator
    Leuplin Inj.(=leuprorelin acetate 3.75mg)

    Investigational drug(=Leuplin Inj.)is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.

    Drug: Leuplin Inj. 3.75 mg

Interventions

  • Single injection, subcutaneous injection

    Also known as: CKD-841

  • Single injection, subcutaneous injection

    Also known as: CKD-841

  • Single injection, subcutaneous injection

    Also known as: CKD-841

  • DrugLeuplin Inj. 3.75 mg

    Single injection, subcutaneous injection

    Also known as: Leuplin.Inj

06

What researchers measure

Primary outcomes

  1. PK(Cmax)

    Cmax(Maximum concentration of drug in plasma) of Leuprorelin

    Time frame: From before injection to up to 1008 hours post injection

  2. PK(AUClast)

    AUClast(Area under the plasma drug concentration-time curve to last measurement) of Leuprorelin

    Time frame: From before injection to up to 1008 hours post injection

  3. PK(AUCinf)

    AUCinf(Area under the plasma drug concentration-time curve extrapolated to infinity) of Leuprorelin

    Time frame: From before injection to up to 1008 hours post injection

  4. PK(AUC7-t)

    AUC7-t(Area under the plasma drug concentration-time curve from 7 days to last measurement) of Leuprorelin

    Time frame: From before injection to up to 1008 hours post injection

  5. PK(CL/F)

    CL/F(Apparent Clearance) of Leuprorelin

    Time frame: From before injection to up to 1008 hours post injection

  6. PK(Vd/F)

    Vd/F(Apparent Volume of Distribution) of Leuprorelin

    Time frame: From before injection to up to 1008 hours post injection

  7. PK(Tmax)

    Tmax(Time to Cmax/Time to Emax) of Leuprorelin

    Time frame: From before injection to up to 1008 hours post injection

  8. PK(t1/2)

    t1/2(Terminal elimination half-life) of Leuprorelin

    Time frame: From before injection to up to 1008 hours post injection

  9. PD(AUEC0-42d below baseline)

    AUEC0-42d below baseline((AUEC that is below the baseline from 0 h to 42 days)) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.

    Time frame: From before injection to up to 1008 hours post injection

  10. PD(AUEC0-28d below baseline)

    AUEC0-28d below baseline(AUEC that is below the baseline from 0 h to 28 days) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.

    Time frame: From before injection to up to 1008 hours post injection

  11. PD(Area under the response (% change from baseline) curve)

    AUEC(Area under the response (% change from baseline) curve) above baseline of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.

    Time frame: From before injection to up to 1008 hours post injection

  12. PD(Tmax)

    Tmax(Time to Cmax/Time to Emax) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.

    Time frame: From before injection to up to 1008 hours post injection

  13. PD(Tmin)

    Tmin(Time to Emin) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.

    Time frame: From before injection to up to 1008 hours post injection

  14. PD(Emax)

    Emax(Maximum % change from baseline of LH/FSH/Estradiol) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.

    Time frame: From before injection to up to 1008 hours post injection

  15. PD(Emin)

    Emin(Minimum % change from baseline of LH/FSH/Estradiol) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.

    Time frame: From before injection to up to 1008 hours post injection

Secondary outcomes

  1. Safety Assessment by evaluating adverse events(AEs).

    Assessment of the safety of subjects by evaluating adverse events(AEs).

    Time frame: From day1 to day 56

07

Study locations

1 site
  • Severance Hospital
    Seoul, Yonsei-ro, Seodaemun-gu 50-1 03722, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2021; primary completion for Oct 2021, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2021
First posted
Apr 12, 2021
StartEst.
Apr 2021
Primary completionEst.
Oct 2021
CompletionEst.
Nov 2021
Last update
Apr 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04840745
Collaborators
Severance Hospital
Responsible party
Sponsor
First posted
Apr 12, 2021
Start date
Apr 2021 (estimated)
Primary completion
Oct 2021 (estimated)
Completion
Nov 2021 (estimated)
Last update
Apr 19, 2021

Study contacts

Min Soo Park, Ph.D
Contact
minspark@yuhs.ac
82-2-2228-0401
Min Soo Park, Ph.D
principal investigator · Severance Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion